GlassScriptPhysician profile
Amity Parker
NPI 1770239436
$13,943.41
in general payments reported to CMS, 2019-2025
63 companies · $3,366 in 2025
The $3,366 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,982 · 2023: $2,225 · 2024: $2,370 · 2025: $3,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,630 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,629.79 |
| Education | $331.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $5,692.46 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $607.23 | 2022-2025 | |
| Lilly USA, LLC | $570.68 | 2022-2025 | Retevmo, Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $487.97 | 2022-2025 | Calquence, Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $464.57 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $367.98 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Regeneron Healthcare Solutions, INC. | $361.91 | 2022-2025 | Libtayo |
| Gilead Sciences, INC. | $288.34 | 2022-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $256.58 | 2023-2025 | Fotivda |
| Pfizer INC. | $254.18 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $241.70 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Genzyme Corporation | $227.56 | 2022-2025 | |
| Abbvie INC. | $215.20 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $192.54 | 2023-2025 | Xpovio |
| Kite Pharma, INC. | $186.37 | 2025 | Yescarta |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $177.83 | 2023-2025 | Zoladex |
| Celgene Corporation | $174.78 | 2023-2025 | Reblozyl, Pomalyst |
| Pharmacosmos Therapeutics INC. | $155.77 | 2024-2025 | Monoferric, Cosela |
| Exelixis INC. | $148.47 | 2022-2025 | Cabometyx |
| Eisai INC. | $145.37 | 2022-2025 | |
| Beigene USA, INC. | $144.82 | 2022-2024 | Brukinsa |
| Incyte Corporation | $137.29 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Pharmaessentia USA Corporation | $136.45 | 2023-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $126.92 | 2022-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $121.45 | 2023-2025 | |
| Genentech USA, INC. | $110.06 | 2023-2025 | Tecentriq, Itovebi, Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $108.25 | 2022-2025 | Ninlaro, Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $103.50 | 2022-2023 | Imbruvica, Epkinly |
| Taiho Oncology, INC. | $102.77 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $100.18 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Array Biopharma INC | $98.60 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Emd Serono, INC. | $95.96 | 2023-2025 | Bavencio |
| Seagen INC. | $93.26 | 2022-2023 | Tukysa, Padcev |
| Mirati Therapeutics, INC. | $81.50 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $79.44 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $77.98 | 2024-2025 | Onivyde |
| Glaxosmithkline, LLC. | $67.17 | 2024-2025 | Ojjaara |
| G1 Therapeutics, INC. | $61.95 | 2022-2023 | Cosela |
| Puma Biotechnology, INC. | $58.64 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $56.21 | 2024-2025 | Orgovyx |
| Jazz Pharmaceuticals INC. | $49.04 | 2025 | |
| Sobi, INC | $47.11 | 2025 | |
| Blueprint Medicines Corporation | $40.55 | 2024 | Ayvakit |
| Astellas Pharma US INC | $40.00 | 2024 | Xospata |
| Novocure INC. | $35.95 | 2025 | Optune Lua (Novottf-200t) |
| Morphosys, US INC. | $35.54 | 2023 | Monjuvi |
| Macrogenics, INC. | $35.31 | 2023 | |
| Coherus Oncology, INC. | $35.15 | 2025 | Loqtorzi |
| Legend Biotech USA INC. | $34.10 | 2025 | Carvykti |
| Stemline Therapeutics INC. | $32.89 | 2023-2025 | Orserdu |
| Amgen INC. | $31.03 | 2023 | Kyprolis, Vectibix, Nplate |
| Agios Pharmaceuticals, INC. | $30.90 | 2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $26.31 | 2024 | Qinlock |
| Accord Healthcare, INC. | $26.28 | 2025 | |
| Sun Pharmaceutical Industries INC. | $25.55 | 2024 | |
| Servier Pharmaceuticals LLC | $22.69 | 2025 | |
| Progenics Pharmaceuticals, INC. | $22.32 | 2023 | Pylarify |
| Spectrum Pharmaceuticals INC. | $22.08 | 2025 | Rolvedon |
| Geron Corporation | $21.23 | 2025 | Rytelo |
| Cti Biopharma Corp. | $18.06 | 2023 | Vonjo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.39 | 2024 | Gilotrif |
| Beone Medicines USA, INC. | $14.09 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amity Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.